Compare APOG & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | AQST |
|---|---|---|
| Founded | 1949 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 820.9M | 809.3M |
| IPO Year | N/A | 2018 |
| Metric | APOG | AQST |
|---|---|---|
| Price | $37.05 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $47.00 | $10.00 |
| AVG Volume (30 Days) | 192.6K | ★ 2.9M |
| Earning Date | 01-06-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $1,391,854,000.00 | $43,397,000.00 |
| Revenue This Year | $6.10 | N/A |
| Revenue Next Year | $1.04 | $51.39 |
| P/E Ratio | $17.87 | ★ N/A |
| Revenue Growth | ★ 1.19 | N/A |
| 52 Week Low | $32.77 | $2.12 |
| 52 Week High | $85.29 | $7.55 |
| Indicator | APOG | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 48.68 |
| Support Level | $35.02 | $5.73 |
| Resistance Level | $36.88 | $6.40 |
| Average True Range (ATR) | 1.12 | 0.35 |
| MACD | 0.57 | 0.05 |
| Stochastic Oscillator | 99.54 | 63.03 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.